The presence of stromal desmoplasia is a hallmark of spontaneous pancreatic ductal adenocarcinoma, forming a unique microenvironment that comprises many cell types. Only recently, the immune system has entered the pathophysiology of pancreatic ductal adenocarcinoma development. Tumor cells in the pancreas seem to dysbalance the immune system, thus facilitating spontaneous cancer development. This review will try to assemble all relevant data to demonstrate the implications of the immune network on spontaneous cancer development.
INTRODUCTION
The pathologist Rudolf Virchow is credited with postulating the concept of a causal link between inflammation and cancer in the nineteenth century. His hypothesis was based upon the observation that leukocytes are often present in malignant tissues, thus claiming that tumors arise from regions of chronic inflammation. 1 The last two decades have provided evidence that Virchoẃ s observation nearly two centuries ago was not only astute, but also pathbreaking. This evidence has shed light on the underlying mechanisms accounting for the strong association between chronic inflammation and tumorigenesis. However, even in the absence of chronic inflammation, virtually all solid carcinomas contain infiltrates of diverse leukocyte subsets, including both myeloid-and lymphoidlineage cells. These infiltrates do not meet the classical definition of an inflammatory immune response, yet they seem to be instrumental in tumor development. Recently, this form of immune-cell infiltration has been described as 'infiltrating immune cells' to encompass both classic inflammation and more subtle involvement of immune cells. As such, these 'infiltrating immune cells' directly influence tumor biology through various factors. 2 Although there is substantial evidence from epidemiological studies that chronic pancreatitis is a risk factor for pancreatic ductal adenocarcinoma (PDAC), in most cases PDAC develops spontaneously in the absence of clinically apparent inflammation. 3 In specimens of sporadic PDAC, which is still a lethal disease constituting the fourth leading cause of death due to cancer, accumulation of immune cells has been described. 4 To date, it is still unclear whether these cells are innocent bystanders or important players in pancreatic cancer development. Therefore, this review will try to assemble all relevant data to demonstrate an intersection of the immune cells with spontaneous cancer development.
CYTOKINES
Cytokines are key mediators of innate and adaptive immunity regulating a broad spectrum of processes including antigen presentation, bone marrow differentiation and cellular activation. 5 Multiple studies exist implicating cytokines and chemokines in various pathologies including cancer. The following section presents evidence of the role of various cytokines in pancreatic carcinogenesis ( Figure 1 , Table 1 ).
Interleukin 6 Several human case-control studies have linked high serum levels of interleukin (IL)-6 with pancreatic cancer. A strong positive correlation was found among tumor stage, cachexia and decreased survival. Importantly, most of the studies were able to justify the use of IL-6 as a prognostic factor for pancreatic cancer progression.
6-11 IL-6 gene polymorphisms were also associated with pancreatic cancer. 12, 13 Two in vivo studies using Kras G12D mice implicated Stat3 signaling in the mechanism underlying the aforementioned clinical associations. 14, 15 In the first study, cerulein-induced inflammation and oncogenic-Kras activation promoted direct epithelial cell-mediated secretion of IL-6 and IL-11. IL-6 and IL-11 subsequently acted in an autocrine manner on epithelial cells, promoting Stat3-dependent proliferation and matrix-metalloprotease7 expression and metastasis, suggesting a cooperative effect between oncogenic-Kras and Stat3 in inflammation-induced PDAC. 15 Moreover, Lesina et al.
14 implicated IL-6/sIL-6R trans-signaling in Stat3 activation and PDAC development. Myeloid cell-derived IL-6 bound to soluble IL-6R and gp130 on the epithelial cell surface and activated Stat3. Stat3 signaling subsequently promoted PanIN progression through transcriptional regulation of anti-apoptotic and proproliferative genes. Recently, a third study confirmed the pivotal role of IL-6/Stat3 signaling axis in PDAC. Kang et al. 16 showed that RAGE (receptor for advanced glycation end products)-mediated induction of autocrine and paracrine IL-6 secretion increased tumor cell pStat3 levels in an autophagydependent manner. Interestingly, pStat3 localized to mitochondria where it promoted adenosine triphosphate production and consequently tumor cell proliferation. Thus, until now three mechanisms have been proposed for IL-6 mediated promotion of PDAC development. All three mechanisms seem to enhance protumorigenic Stat3 signaling and may act in concert to potentiate PDAC progression.
Interleukin 1
The interleukin 1 family contains among others IL-1a, IL-1b and IL-1 receptor antagonist (IL-1ra), all of which interact with membrane-bound IL-1R type I or II. 5 IL-1a levels have been found to be increased in tumor tissue and associated with compromised survival of pancreatic cancer patients. 17, 18 Furthermore, increased IL-1RI expression in tumor tissue was found dependent on the occurrence of liver metastasis 19 In addition, IL-1b gene and promoter polymorphisms coincided with worsened disease outcome, cachexia and enhanced acute phase protein response 7, 20 . IL-1b levels were also implicated in rare pancreatic neuroendocrine tumors and intraductal papillary mucinous neoplasms. 21, 22 In contrast, elevated serum IL-1ra levels have been correlated with increased patient survival, possibly through antagonizing IL-1R signaling. 8 In vivo, aberrant Kras activation enhanced IL-1a production from pancreatic tumor tissue, which in turn induced nuclear factor-kBdependent IL-1a and p62 expression. IL-1a and p62 constituted a feedforward loop sustaining nuclear factor-kB activation and resulting in enhanced tumorigenesis and liver metastasis. 18 Orthotopic mouse models and xenograft studies further underlined the importance of nuclear factor-kB in mediating protumorigenic effects of IL-1a as well as IL-1b. 23, 24 An association was also found between nitric oxide production from cancerassociated fibroblasts and IL-1b secretion from tumor cells. 25 Along the same lines, IL-1b derived from granulocytes and macrophages within the tumor microenvironment was found to cooperate with stromal cell-derived factor 1a from tumor cells in stimulating inflammation, angiogenesis and tumor growth. 26 Multiple in vitro studies have also provided evidence on the importance of IL-1 in enhancing tumor cell growth, invasion, migration, chemoresistance and induction of angiogenesis. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Taken together, IL-1 acting primarily through nuclear factor-kB seems to promote pancreatic tumorigenesis and malignancy.
Interleukin 10 An association of IL-10 with pancreatic cancer has been proven by multiple clinical studies. In all cases, tissue and serum levels of IL-10 were upregulated in pancreatic cancer patients and strong positive correlations were found between tumor stage and poor differentiation status. [38] [39] [40] [41] [42] [43] [44] [45] [46] An IL-10 gene polymorphism has also been implicated in determining pancreatic cancer risk. 47 Mechanistically, the above-mentioned correlations could be explained by the known immunosuppressive function of IL-10. IL-10 was shown to induce an anti-inflammatory microenvironment in cancer patients, resulting in reduced effector cell function (for example, natural killer cells, dendritic cells (DCs)) and a shift toward Th2 cytokines. 41, 44, 45, 48 Elevated IL-10 levels might therefore assist the pancreatic tumor cells to escape immune recognition and elimination.
Other cytokines Evidence of the influence of other cytokines on pancreatic cancer development and progression is sparse and requires further investigation. 49 In the case of tumor necrosis factor-a, for example, studies so far have been contradictory, showing either an association of pancreatic cancer with elevated tumor necrosis factor-a in serum 48, 50 or failing to detect differences. 8 
CHEMOKINES
Chemokines are chemotactic cytokines that have an important role in orchestrating cellular migration (leukocytes/fibroblasts/ keratinocytes) during tissue development and inflammation. Chemokines can be classified into CXC, CC, CX3C or C, depending on the position of the conserved cysteine residue. The following section highlights chemokines shown to be involved in pancreatic tumorigenesis according to their structural classification ( Figure 1 and Table 1 ).
CXC chemokines CXC chemokines include among others CXCL3 (GROgamma), CXCL4 (PF4), CXCL5 (ENA-78), CXCL8 (IL-8), CXCL12 (SDF-1) and CXCL13 (BLC). 51 Many of these chemokines, for example, CXCL5 52 and CXCL12/CXCR4, 53 have been primarily associated with tumor angiogenesis and metastasis, but not with primary tumor establishment. The strongest association between pancreatic cancer angiogenesis and dissemination has been made for IL-8/ CXCR2. 54, 55 In addition, serum IL-8 has been reported as a predictor for pancreatic cancer prognosis and increased tumor xenograft growth. 56 Interestingly, CXCR2-signaling was also shown to have a role in tumor-stroma interactions, where increased secretion of CXCR2 ligands from invasive PDAC cells in Kras
G12D
Tgfbr2KO mice stimulated stromal fibroblasts to produce connective tissue growth factor, negatively influencing survival. 57 CC chemokines Currently, of the known CC chemokines, only CCL2 (MCP1) and CCL5 (regulated upon activation normal T cell expressed and presumably secreted (RANTES)) have been associated with primary tumor-immune crosstalk. Other CC chemokines, for example, CCL21 58 and CCL20, 59 are mainly involved in tumor cell invasion and are thus not discussed here.
MCP1 is a monocyte chemoattractant, associated with elevated tumor-associated macrophage content in multiple malignancies. 60 In PDAC tissue MCP1 seems to be tumor stroma-derived. 61 Interestingly, pancreatic cancer tissue and serum MCP1 showed a positive association with tumor macrophage infiltration and a negative correlation with tumor cell proliferation, suggesting that the recruited macrophages induced a proinflammatory microenvironment counteracting tumor progression. 62 Furthermore, spontaneously developed tumors in C57BL/6 EL-TGF-a, Trp53KO mice, exhibited decreased levels of MCP1 and CD8 þ T cells, indicative of immune suppression. 63 The importance of MCP1 in monocyte attraction was also shown in orthotopically grown tumors, where intratumoral MCP1 injections increased adhesion between immune and endothelial cells. 64 Taken together, MCP1 mediates intratumoral monocyte infiltration, which so far has been associated with tumor inhibition.
A second proinflammatory chemokine involved in monocyte attraction is RANTES. 60 PDAC cells are capable of producing RANTES, as has been shown in human specimens 46 and cell lines. 65 A recent orthotopic tumor study provided evidence that RANTES may mediate immune evasion of tumor cells by recruiting CCR5 þ T reg cells into the tumor microenvironment. 46 In addition, RANTES can be produced by mesenchymal stromal cells that actively migrate into primary pancreatic tumors influencing cancer progression. 66, 67 Thus, RANTES seems to be important in enhancing tumor-promoting inflammation, immune evasion and mesenchymal stromal cell function. In human: positively correlates with tumor stage, cachexia and decreased survival. [6] [7] [8] [9] [10] [11] 14 In mouse: mediates autocrine stimulation of acinar cells in Kras G12D mice after cerulein-induced inflammation; mediates PanIN-progression via sIL-6R/gp130-dependent Stat3 activation; induces mitochondrial translocation of Stat3 leading to increased ATP production and pancreatic tumor cell proliferation. [14] [15] [16] IL-1
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In human: increases tumor tissue IL-1a correlated with disease prognosis; IL-1b levels are associated with pancreatic neuroendocrine tumors and IPMNs; elevated serum IL-1ra levels correlate with increased patient survival. 8, 17, 18, 21, 22 In mouse: IL-1a/p62 is required for sustained NF-kB-activation, increased tumorigenesis and metastasis in Kras G12D mice; IL-1a as well as IL-1b mediate protumorigenic effects in orthotopic mouse model; granulocyte/macrophage-derived IL-1b is associated with increased tumor growth. In human: is associated with proinflammatory macrophage infiltration and inhibition of tumor cell proliferation. 61, 62 In mouse: decreased MCP1 levels are associated with reduced tumor CD8 þ T-cell numbers in C56BL/6 EL-TGF-a, Trp53-KO mice; is involved in tumor monocyte infiltration. 63, 64 
RANTES Epithelial cells T cells, fibroblasts
In human: PDAC cells produce RANTES. 46 In mouse: is involved in the recruitment of T reg cells, promoting tumor immune evasion; mediates mesenchymal stromal cells homing into pancreatic tumor tissue enhancing tumor growth. 46, 66, 67 Abbreviations: ATP, adenosine triphosphate; CXCR2, CXC-motiv-chemokine receptor 2; IL, interleukin; IPMN, intraductal papillary mucinous neoplasm; KO, knockout; NF-kB, nuclear factor-kB; PDAC, pancreatic ductal adenocarcinoma; RANTES; regulated upon activation normal T cell expressed and presumably secreted.
Immune system in spontaneous pancreatic cancer SM Wö rmann et al CX3C chemokines CX3CL1 (Fraktalkine), the only chemokine belonging to the CX3C chemokine group, is expressed in the central nervous system, where it binds to CX3CR1. 68 In human pancreatic cancer CXC3R1 presence has been correlated with perineural invasion and early tumor recurrence. 69 In vitro CX3CL1 enhanced integrin-mediated adhesion of CX3CR1-positive tumor cells to neural cells. 69 Furthermore, in vivo xenograft studies showed that only CX3CR1-positive transplanted PDAC cells were able to infiltrate local nerves.
69 CX3CL1/CX3CR1 may thus have an important role in regulating PDAC neurotropism. 69 
TUMOR-ASSOCIATED MACROPHAGES
The main population of inflammatory cells in solid tumors is formed by tumor-associated macrophages (TAMs) derived from either recruited blood monocytes or resident tissue macrophages. 70 Different states of activation and polarization have been described for TAMs. 71 On the one hand, Toll-like receptor (TLR)-ligands (for example, lipopolysaccharide) or interferon-g (IFN-g) elicit classical/M1-activated macrophages, which act against intracellular pathogens as well as tumor cells, thus driving an anti-tumorigenic response. 71 On the other hand, 'alternative'/M2-activated macrophages, stimulated by IL-4, IL-10, IL-13, FcgR-signaling or hypoxia, initiate protumorigenic actions primarily by promoting angiogenesis and invasion, repairing tissue damage and fine-tuning inflammatory responses. 71 Integration of various signals derived from immune cells (for example, IL-4-producing Th2 cells), tumor cells (for example, IL-10) or dysregulated neighboring tissues (for example, hypoxic signals) determines the final composition of TAM subtypes, highlighting the dynamic nature of TAM polarization. 71 Accordingly, results of a recent study evaluating macrophage infiltration into human pancreatic cancer provided evidence of two different types of TAMs with opposite functions, characterized by the expression of either CD68 (general macrophage marker) or CD163 (specific M2 macrophage marker). 61 Importantly, whereas increased amounts of CD68-positive TAMs tended to associate with shorter survival after pancreatic tumor resection, CD163-positive TAMs conferred a significant survival advantage. 61 In another study, however, M2-polarized TAMs were shown to massively accumulate in the invasive front of pancreatic cancer. 72 The extent of their infiltration was associated with increased lymphangiogenesis and poor prognosis. 72 Furthermore, the ratio of M1 to pan-macrophages (%M1) has recently been associated with longer survival in pancreatic cancer. 73 Thus, simple M1/M2 classification of macrophages may not be enough in terms of their effect on tumor promotion, which might also depend on their specific localization in the tumor microenvironment as well as the stage of tumor development (initiation versus progression). 71 Insight into the recruitment and role of TAMs in pancreatic oncogenesis originated from genetically engineered mouse models for PDAC. Factors such as granulocyte macrophage colony-stimulating factor expressed in the tumor or in its microenvironment have the capacity to regulate recruitment, maturation and differentiation of TAMs. In addition to being evident in invasive carcinomas, TAMs seem to colonize the tumor very early around PanIN lesions of the lowest grade. 74 Moreover, TAMs are not only innocent bystanders, but also important regulators of PanIN progression. TAMs were shown to be the predominant source of IL-6 in PanIN lesions of KrasG12D mice, initiating STAT3 signaling and promoting cancer development. 14 In addition, NFkB-activated monocytes were implicated in stimulation of pancreatic cancer cell proliferation via sonic hedgehog production. 75 The importance of the polarization state of TAMs has been highlighted in mouse and human studies. Using an agonist antibody against the co-stimulatory molecule CD40 enabled reprograming of M2-like TAMs into anti-tumor M1-like TAMs. CD40-activated macrophages rapidly infiltrated pancreatic tumor, became tumoricidal and facilitated the depletion of tumor stroma in human and mouse models, thus restoring tumor immune surveillance 76 ( Figures 2 and 3 ). In human specimens of PDAC, numerous MDSCs were detected not only in the stroma, but also in the peripheral blood, bone marrow and spleen, suggesting that MDSCs are systemically expanded and recruited to the site of the tumor. 78, 79 The mechanisms through which MDSCs are attracted, however, are not fully clear. In two recent publications, the growth factor granulocyte macrophage colony-stimulating factor secreted by pancreatic tumors has been unveiled as the early and important mediator of MDSCs recruitment. Disruption of the paracrine circuit between tumor cells and MDSCs based on granulocyte macrophage colony-stimulating factor inhibited MDSC accumulation, restored CD8 þ cytotoxic T cell immunity and helped to overcome immunosuppressive effects on local killer T cells 80, 81 (Figures 2 and 3 ).
MYELOID-DERIVED SUPPRESSOR CELLS

TUMOR-ASSOCIATED NEUTROPHILS
Although early studies indicated that neutrophils regulate cytotoxic T cells to attack tumor cells, past evidence suggests a potential of these cells in cancer development and metastasis. 82 In fact, the presence of tumor-associated neutrophils (TANs) has been reported for several cancer types. Association studies suggest that the density of TANs is linked to a higher tumor grade and shorter survival period. 83 Recently, a comprehensive analysis of neutrophils in pancreatic cancer types revealed accumulation of TANs only in a small subset of pancreatic neoplasms. Their role in pancreatic oncogenesis, however, still remains unclear. Using an immunocompetent mouse model of PDAC, a recent study suggests that TANs are involved in shaping the metastatic niche through the release of matrixmetalloprotease9 (Figures 2 and 3) . 84 MAST CELLS Mast cells are characterized by cytosolic granules containing humoral immunity mediators required for limiting infectious spread and mediating tissue repair. 85 In pancreatic cancer, accumulating evidence suggests that mast cells promote tumor progression. Analysis of human pancreatic cancer specimens revealed increased numbers of mast cells in malignant lesions correlating with lymph node metastasis, intratumoral microvessel density, reduced survival [86] [87] [88] [89] and poor prognosis after curative resection, especially when mast cell infiltration occurred in the intratumoral border zone. 90 Chang DZ et al. 89 observed an early accumulation of mast cells in premalignant PanINs, with a gradual distribution towards the invasive edges in malignant PDAC, associating mast cell infiltration with tumor progression. Interestingly, an omega-6 fatty acid-rich diet seems to enhance mast cell infiltration into pancreatic preinvasive lesions and to accelerate tumor development, further implicating mast cells in early tumor onset. Mechanistically, mast cell degranulation can induce endothelial cell proliferation, counteracting hypoxia and associated tumor cell apoptosis. 87, 91 Mast cells may also directly influence pancreatic cancer cell expansion through stimulation of c-kit, which is found to be increasingly expressed on tumor cells. 86 To date, data suggest that mast cells are able to promote pancreatic cancer progression by accumulating at the leading edge of tumors subsequently stimulating angiogenesis, invasion and metastasis 92 ( Figures 2  and 3 ).
DENDRITIC CELLS
DCs are important mediators of immunity and tolerance, functioning, when fully activated, as professional antigen-presenting cells. [93] [94] [95] Tumor cells have the capability to evade immunosurveillance and establish an immunosuppressive environment inhibiting maturation and function of DCs in vitro 96 and in tumor-bearing hosts. In various clinical studies of pancreatic cancer, for the first time by Dallal et al. 97 and later by Bellone et al., 98 as well as in studies of several other cancer types 93, [99] [100] [101] [102] decreased numbers of tumor-associated, fully activated DCs were observed. Importantly, abnormal myelopoesis as a major mechanism causative for DC defects in cancer, resulting in increased production and accumulation of immature DCs has been verified. 103 Evidentiary, previous studies have demonstrated that DC differentiation and antigen presentation might be suppressed by a pancreatic cancer cellconditioned medium in vitro. 104, 105 Moreover, circulating DCs in the peripheral blood of pancreatic cancer patients are decreased in number and impaired in function. 106 By investigating circulating myeloid and lymphoid DCs in patients with non-resectable pancreatic cancer, high levels of circulating myeloid DCs were related to improved survival time and proposed as an independent favorable prognostic factor in patients with nonresectable pancreatic cancer. 107 In human PDAC tissues, significantly increased levels of immune-modulatory and chemotactic factors (IL-6, transforming growth factor-b (TGF-b), IDO, cyclooxygenase-2, CCL2 and CCL20) as well as immune cellspecific markers originating from macrophages, myeloid and plasmacytoid DCs were detected. Low levels of DC makers were negatively correlated with the survival rate. 61 Fukunaga et al. 108 have previously reported a positive correlation between DC infiltration, CD4 þ /CD8 þ tumor-infiltrating lymphocytes cells and good prognosis in PDAC.
Adaptive Immune Response
In general, the tumor-promoting function of DCs might be exerted via active suppression of T-cell function, in particular CD8 þ T cells, primarily mediated by l-arginine arginase1 metabolism or TGF-b-dependent T reg proliferation. 109, 110 Furthermore, DCs from peripheral blood and lymphoid organs, especially DCs located near the tumor site, exhibited enhanced accumulation of lipids resulting in impaired soluble protein processing, ineffective tumor-associated antigen presentation and diminished tumorspecific T-cell activation. 111 The impaired DC differentiation and function can be referred to different tumor-derived factors, such as IL-6, vascular endothelial growth factor, M-CSF, and more recently to hypoxia-inducible factors present in the tumor microenvironment. 112, 113 Under hypoxia, human DCs promoted skewing of the immune phenotype from Th1 to Th2, thus dampening the anti-tumor immune response. 114 The latter was recently confirmed by pancreas-specific expansion of DC populations together with simultaneous Th2 polarization in mouse models of both benign and malignant pancreatic disease and in human pancreatic cancer tissue, resulting in enhanced malignant transformation and growth of pancreatic tumors. Thus, DCs seem to accelerate pancreatic tumorigenesis by capturing antigen from the injured pancreas and priming naïve T cells toward protumorigenic, Th2-deviated CD4 þ T cells. Interestingly, this predominant Th2 polarization can be mediated by MyD88 blockade in DC cells as previously shown in mice [115] [116] [117] [118] ( Figures 2 and 3) . 
TUMOR-INFILTRATING LYMPHOCYTES
Cytotoxic CD8 þ T-lymphocytes are important components of tumor-specific cellular adaptive immunity, efficiently recognizing their tumor targets and attacking tumor cells presenting tumorassociated antigen peptides with the major histocompatibility complex class I on their surface. CD8 þ cytotoxic T cells are capable of eliminating tumor cells via IFN-g-mediated direct effects on malignant cells and via induction of macrophage tumoricidal activity. [119] [120] [121] [122] [123] Previous studies of a variety of cancer types provide evidence for an anti-tumor activity and a favorable effect on the clinical outcome and patient survival for tumorinfiltrating CD8 þ cells 124 for example, in colorectal, 125, 126 ovarian, 127, 128 esophageal, 129 renal, 130 lung, 131 and pancreatic 108, 132 tumors. In human pancreatic cancer, CD8 þ T-lymphocytes represent the predominant T-lymphocyte subset 132 and are associated with favorable clinical outcome and significantly prolonged survival. 73, 108, 133 CD8 þ cells were further linked to reduced tumor growth as previously shown in a xenograft murine model. 133 However, there is evidence for cytolitic immune escape in pancreatic cancer, as the number and function of CD8 þ T cells circulating in the blood of pancreatic cancer patients was found to be compromised compared with healthy donors. 134 Further, CD8 þ T cells (CD8 þ CD103) bearing markers analogous to the gut intraepithelial lymphocytes (CD8 þ aEb7 þ ) were found to be mainly located in the fibrous stroma distant from cancer cells (their potential effector domain). 132 These findings, together with the previously reported downregulation of the adhesion molecule ligand E-cadherin 135 on intercellular junctions as well as the overexpression of TGF-b by pancreatic cancer cells, 136 lead to the assumption that pancreatic cancer cells may escape the cytolitic effect of cytotoxic T cells by promoting their aggregation in fibrous tissue. 132 Moreover, downregulation of activation markers on cytotoxic CD8 þ
CD18
þ T-lymphocytes may diminish their cytotoxic activity toward pancreatic cancer. 132 The effect of TGF-b was further elucidated in a mouse model, where TGF-b gene silencing in combination with RIG-I signaling activation via bifunctional ppp-siRNA (ppp-TGF-b) resulted in the recruitment of activated CD8 þ T cells to the tumor along with reduced frequency of CD11b þ Gr-1 þ myeloid cells thereby significantly prolonging survival. Interestingly, treatment of mice with established pancreatic tumor with ppp-TGF-b resulted in enhanced IFN-g expression, indicating a shift from Th2 toward a Th1 immunophenotype. 137 Hypothesizing TGF-b blockade as a source for this anti-tumor effect, it was previously shown that exactly this blockade together with type I INF reduced the suppressive function of MDSC. 82, 138 The expansion of MDSC, which are capable of effectively suppressing CD8 þ T cells, is a hallmark in pancreatic cancer 74, 139, 140 (Figures 2 and 3 ).
CD4 þ T cells and subtypes
Th1/Th17 and Th2 cells. In most human cancer types, Th1 cells and their produced cytokines, for example, IFN-g, strongly contribute to a favorable clinical outcome. For other T-cell populations, such as Th17 cells, a pro-or anti-tumor role could not be clearly defined (Figure 2 ). Previous studies of various cancer types described a protumorigenic effect of IL-17A and Th17 cells. [141] [142] [143] [144] [145] [146] [147] However, in several studies a tumor-protective role of Th17 cells could be shown. 148 In murine pancreatic cancer, an increase of Th17 cells in the tumor microenvironment retarded pancreatic tumorigenesis and contributed to improved survival, 149 whereas more recently in human pancreatic cancer, increased levels of Th17 cells and their related cytokines accounted invasion and metastasis, affecting patient prognosis. 142, 150, 151 Th2 cells seem to have protumorigenic effects (Figures 2 and 3) ; they are related to poor prognosis and reduced survival in human cancers.
152 Th2 responses exhibit tumor-promoting function in pancreatic cancer 153 and other carcinomas, thus accelerating disease progression and reducing survival. [154] [155] [156] [157] [158] [159] The exact pathomechanisms and signaling pathways behind these observations are not completely understood. Various studies demonstrated evidence for a general Th2 shift in pancreatic cancer. 42, 153, 160, 161 Thereby, a predominance of Th2 cytokines (IL-5, IL-6 and IL-10) and especially IL-13 was found in the plasma of pancreatic cancer patients. 42, 160, 161 In addition, the Th1 immune response in the peripheral blood of pancreatic cancer patients seems to be indirectly inhibited by tumor cell-derived TGF-b and IL-10, whereas an overall Th1 response might be restrained by increased secretion of IL-4 and decreased production of IFN-g and IL-12 from stimulated peripheral blood mononuclear cells. 42, 44, 160 Further, a predominant infiltration of pancreatic cancer stroma by Th2 (GATA3 þ ) in contrast to Th1 (Tbet þ ) cells correlated with disease progression (Figure 3) . Thereby, the ratio of GATA3 þ / Tbet þ tumor-infiltrating lymphocytes was proposed as an independent predictive marker for survival after surgery in patients with (stage IB/III) pancreatic cancer. Importantly, this pro-tumor-specific Th2 immune-deviation was assumed to be local rather than systemic, as the anti-viral Th1 cell immunity was retained in these patients. 153, 161 The proposed Th2 response can be induced by thymic stromal lymphopoietin, a cytokine regulating T-cell maturation through DC activation. 162 Thymic stromal lymphopoietin secretion from cancer-associated fibroblasts is upregulated in pancreatic cancer due to increased stimulation from tumor-derived tumor necrosis factor-a and IL-1b. Thymic stromal lymphopoietin-activated DCs gain the capability to migrate to the draining lymph nodes and promote Th2 cell infiltration into the tumor microenvironment under the influence of Th2-attracting chemokines thymus and activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22).
153 Th2-released cytokines, in particular IL-13 and IL-5, may contribute to fibrosis by increasing extracellular matrix deposition and collagen synthesis. 163 In addition, IL-13 was demonstrated to enhance proliferation by acting as an autocrine growth factor in PDAC. 164, 165 Importantly, IL-13 also attenuates Th1-driven, cell-mediated immune responses through its effects on monocytes/macrophages, causing downregulation of proinflammatory cytokines, IL-1, IL-6 and tumor necrosis factora, and chemokines, IL-8 and MIP-1a, and inhibiting antibodydependent cellular cytotoxicity. 166, 167 However, the Th2 immune phenotype can be reversed into pre-existing Th1 immune phenotype via the induction of IFN-g by IL-12 and IL-27 treatment, subsequently fostering tumor-suppressive function and suppressing fibroblast-mediated collagen synthesis while inhibiting IL-5, IL-13 and granulocyte macrophage colonystimulating factor. 168 Th2 cells also promote differentiation of M2 macrophages by both Th2 cytokine release (IL-4, IL-5 or IL-13) and by tumor antigen-specific recognition of peptide-MHC class II complexes on the surface of differentiating monocytes. In summary, a complex cross talk among tumor cells, cancerassociated fibroblasts and T cells leading to enhanced Th2 inflammation with significant impact on poor survival has been proposed 153 ( Figures 2 and 3) .
T regs . In a variety of human cancers, tumor-infiltrating lymphocytes clearly correlate with patient survival. 125, [169] [170] [171] Thereby, CD4 þ CD25 þ Foxp3 þ tumor-infiltrating lymphocytes, namely T regs , suppress the adaptive immune response and correlate with poor prognosis in cancer. 172 In pancreatic cancer, T regs control the anti-tumor immune response from the premalignant stage to established cancer, and are a marker of poor prognosis. 173 In murine pancreatic cancer the progression from normal histology to PanIN and PDA was paralleled by a progressive predominant infiltration of CD45 þ cells. However, immunosuppressive cells including TAMs, MDSCs and T regs , dominated both preinvasive lesions and invasive cancer. In particular, Foxp3 þ T regs were shown to participate in the early infiltration of preinvasive lesions and increase during progression of PDAC, corresponding with a decrease in CD8 þ T-cell infiltration and contributing to poor clinical outcome and overall survival, thus confirming the human findings. 173, 174 Mechanistically, T reg homing into the tumor microenvironment might be related to tumor cell-derived CCL5 and TGF-b, as previously shown in a murine model for inoculated Panc02 cells, fostering T reg recruitment and conversion of CD4 þ
CD25
À naive T cells into T regs . 46, 175 T regs that are not able to produce IL-2 themselves, rely on an exogenous source for IL-2 to maintain and increase their suppressor function. Thus, DCs, which in part constitutively express IL-2, are in general capable of stimulating T regs and promoting their protumorigenic function. 176, 177 For pancreatic cancer these findings are yet to be proven (Figures 2 and 3) .
PATTERN RECOGNITION RECEPTORS
TLRs are the most well-described pattern recognition receptors and are expressed on innate immune cells. 178 TLRs recognize conserved molecular patterns in microbes (pathogen-associated molecular patterns) and endogenous ligands (danger-associated molecular patterns (DAMPs)). While pathogen-associated molecular patterns are small molecular sequences consistently found on pathogens, DAMPs evolve as diverse byproducts at sites of inflammation or cellular injury, thus linking environmental stimuli to innate immunity. 179 Beyond its implication in immune defense, increasing evidence suggests an important role of these receptors in tumor development. Pattern recognition receptors were found to be expressed in selected neoplastic tissues, such as pancreatic cancer. Two recent publications revealed that both pathogen-associated molecular pattern and DAMP receptors are present in human PDAC specimens. 115, 180 Genetic inhibition of the classical pathogen-associated molecular pattern-receptor TLR4 was protective against pancreatic cancer. This beneficial effect depended on TRIF, rather on MyD88 adaptor protein. Inhibition of the adaptor protein MyD88 accelerated tumorigenesis and exacerbated concomitant inflammation. These MyD88-related effects were mediated by DCs that stimulated pancreatic antigen-restricted Th2-deviated CD4 þ T cells. 115 While blocking of TLR4 signaling exerts divergent effects on pancreatic oncogenesis, inhibition of TLR7 was shown to modulate stromal inflammation, thereby slowing down pancreatic cancer development. In addition to the viral byproducts as natural ligands of TLR7, DAMPs were also shown to bind to this receptor. Similar to colon and lung cancer, the pancreatic tumor microenvironment harbors substantial amounts of DAMPs. Ligation of TLR7 involved various signaling pathways such as Stat3, Notch or mitogen-activated protein kinases, all of which are known to promote carcinogenesis in the pancreas. 180 Thus, both studies clearly demonstrate an important role of TLRs in pancreatic cancer development (Figure 3) . þ T cells correlate with favorable clinical outcome and improved survival, whereas the effect of CD4 þ T cells depends on their differentiation into subtypes (Th1, Th2, Th17, T regs ); Th2 cell infiltrates are a strong predictive marker over Th1 for reduced survival and enhanced tumor growth; Th17 cells exhibit mostly protumorigenic effects; T regs increase in numbers during the progression of pancreatic cancer from early lesions to advanced cancer, fostering a decrease in CD8 þ T-cell infiltration and participating in poor clinical outcome and overall survival. The influence of DCs on pancreatic tumor depends on their maturation stage, illustrated by pancreatic cancer cells suppressing DC differentiation and antigen presentation. Further, low levels of DC markers have been associated with reduced survival. The relevance of TAMs seems to be bifunctional: M2 macrophages fostering Th2 shift exhibit similarity to Th2 protumorigenic function, whereas M1 macrophages as well as M1-stimulated Th1 cells bear anti-tumorigenic effects. TANs are involved in higher tumorgrade and compromised survival. Mast cells are suggested to promote pancreatic cancer progression by accumulating at the leading edge of tumors subsequently stimulating angiogenesis, invasion and metastasis. Finally, cellular immunity is greatly influenced by cytokines and chemokines, which may also derive from tumor cells themselves (for example, IL-6, IL-1 and IL-10). These soluble immune mediators further enrich the complexity of the tumor microenvironment, affecting immune-cell infiltration and effector function. All together, the dynamic network among immune cells themselves, the tumor cells and the microenvironment implicate an important role in tumor development and progression ( Figure 3) .
CONCLUSION AND PERSPECTIVES
The gathered data clarify the relationship between cancer and immunity, and provide new insights in development and treatment of pancreatic cancer (Figure 3 ). While we are only starting to appreciate the tumor-promoting effects of the immune system, new strategies to combat pancreatic cancer should include not only chemotherapeutic agents but also substances that interfere with the local immune response. ABBREVIATIONS BLC, B lymphocyte chemoattractant; DAMP, danger-associated molecular pattern; DC, dendritic cell; IDO, indoleamine 2,3-dioxygenase; IFN-g, interferon-g; IL-1ra, IL-1 receptor antagonist; IL-6, Interleukin 6; INF, Interferon; MCP1, monocyte chemoattractant protein 1; M-CSF, macrophage-colony stimulating factor; MDC, macrophage-derived chemokine; MDSC, myeloid-derived suppressor cell; PDA, pancreatic ductal adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma; RANTES, regulated upon activation normal T cell expressed and presumably secreted; SDF-1a, stromal cell-derived factor 1a; TAM, tumor-associated macrophage; TAN, tumor-associated neutrophil; TARC, thymus and activation-regulated chemokine; Th1, T helper type 1 cells; Th2, T helper type 2 cells; TLR, Toll-like receptor; TRIF, TIR-domaincontaining adapter inducing interferon-b
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